Compare
Orchestra BioMed Holdings, Inc. vs Premier Air Charter Holdings Inc. vs ClearPoint Neuro, Inc. vs Cytosorbents Corp
| Latest fiscal year | Orchestra BioMed Holdings, Inc. OBIO | Premier Air Charter Holdings Inc. PREM | ClearPoint Neuro, Inc. CLPT | Cytosorbents Corp CTSO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $33.48M | $31.88M | $36.97M | $37.06M |
| Revenue growth (YoY) | n/m | +53.6% | +17.8% | +4.1% |
| Gross margin | n/a | 10.6% | 61.4% | 71.5% |
| Operating margin | -154.7% | -8.5% | -65.4% | -39.8% |
| Net margin | -157.4% | -12.1% | -69.1% | -22.1% |
| Net income | -$52.70M | -$3.87M | -$25.54M | -$8.20M |
| EPS (Diluted) | -$1.11 | -$0.01 | -$0.90 | -$0.13 |
| Operating cash flow | -$48.96M | $1.15M | -$23.93M | -$12.38M |
| Free cash flow | -$49.45M | -$1.40M | -$24.45M | -$12.54M |
| Cash & equivalents | $34.69M | n/a | $45.92M | $6.25M |
| Total assets | $114.86M | $36.05M | $97.75M | $44.18M |
| Total liabilities | $51.48M | $32.08M | $69.73M | $38.28M |
| Shareholders' equity | $53.57M | $3.97M | $28.02M | $5.90M |
| Return on year-end equity | -98.4% | -97.4% | -91.1% | -138.9% |
| Shares outstanding | 57.03M | 280.85M | 29.37M | 62.80M |
Revenue, most recent five fiscal years
| Fiscal year | Orchestra BioMed Holdings, Inc. | Premier Air Charter Holdings Inc. | ClearPoint Neuro, Inc. | Cytosorbents Corp |
|---|---|---|---|---|
| Latest | $33.48M Ended 2025-12-31 | $31.88M Ended 2025-12-31 | $36.97M Ended 2025-12-31 | $37.06M Ended 2025-12-31 |
| 1 year earlier | $2.64M Ended 2024-12-31 | $20.75M Ended 2024-12-31 | $31.39M Ended 2024-12-31 | $35.59M Ended 2024-12-31 |
| 2 years earlier | $2.76M Ended 2023-12-31 | n/a | $23.95M Ended 2023-12-31 | $31.08M Ended 2023-12-31 |
| 3 years earlier | $3.53M Ended 2022-12-31 | n/a | $20.55M Ended 2022-12-31 | $34.69M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $16.30M Ended 2021-12-31 | $43.17M Ended 2021-12-31 |